BLyS inhibitor monoclonal antibody

This page covers all BLyS inhibitor monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting B-lymphocyte stimulator (BLyS/BAFF), B-lymphocyte stimulator (BLyS), BLyS (B-lymphocyte stimulator / BAFF).

Targets

B-lymphocyte stimulator (BLyS/BAFF) · B-lymphocyte stimulator (BLyS) · BLyS (B-lymphocyte stimulator / BAFF)

Marketed (3)

• Belimumab Injection [Benlysta] · National University Hospital, Singapore · Immunology
  Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS), reducing B cell proliferation and autoantibody production in systemic lupus erythematosus.
• Belimumab plus Early Vaccination · Human Genome Sciences Inc., a GSK Company · Immunology
  Belimumab inhibits B-lymphocyte stimulator (BLyS) to reduce autoreactive B cells, combined with early vaccination to enhance immune response.
• Belimumab (GSK1550188) · GlaxoSmithKline · Immunology
  Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS), reducing B cell proliferation and autoantibody production in systemic lupus erythematosus.

Phase 3 pipeline (1)

• Belimumab Injection · Nanjing University School of Medicine · Immunology
  Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS), reducing B cell proliferation and autoantibody production in autoimmune diseases.

Patent intelligence

• blys inhibitor monoclonal antibody patent landscape — aggregated cliff calendar, attackable patents, originator estates